title: [EFFECTS OF URSODEOXYCHOLIC ACID IN STANDART INTERFERONTHERAPY OF PATIENTS WITH CHRONIC HEPATITIS C AND B].
abstract: With the purpose to estimate the efficiency of ursodeoxycholic acid (UDCA) in standard antiviral therapy (SAT) of chronic hepatitis C or/and B 580 patients with the chronic virus hepatitis enrolled in this study. During 48 weeks patients with hepatitis B and B+D received peg-interferon, and patients with C and B+C hepatitis received combined peg-interferon and ribavirin. 1st group of 300 patients (B--130, C--96, B+C--73, B+D--10; 190 men, 110 women, middle age of 32.9 ± 10.1 years) additionally took UDCA not less than 6 months. The 2nd group of 280 patients (B--133, C--98, D+C--26, B+D--14; 172 men, 108 women, middle age of 35.9 ± 7.5 years) took only SAT. ALT, AST, bilirubin, γ-glutamiltranspeptidase, alkaline phosphatase levels, and blood analysis were evaluated. Due to UDCA normalization of the raised ALT and AST levels was observed by 6th week of SAT in 50 patients (from 80 patients with initially raised ALT and AST) of 1st group. ALT and AST levels reached norm in 1st group by 12th week whereas in 60 (21.4%) patients of 2nd group ALT, AST remained raised. Cholestasis remained at 30% of patients in the 1st group by the beginning of SAT and in 35.7% of patients in the 2nd. By 12th week cholestasis was observed only at 3.3% of patients of 1st group (32.1%--in the 2nd group). By 24th week the raised level of bilirubin remained in 7.1 % of patients in the 2nd group whereas in 1st group cholestasis was only at 1 patient. Decrease of hemoglobin level by 12th week of treatment within 110-100 g/l was observed at 10% of patients in 1 group, at 17.9%--in the 2nd. By 24th week anemia was observed only in 2nd group (1st group--0%; 2nd group--14.3%). Decrease in platelets level in the first 2 months of treatment was in both groups, but normalization of their quantity went earlier in 1st group. By 12th week of treatment level of platelets in all patients receiving UDCA was higher than 120,000/ml (3.6%--in the 2nd group). UDCA within SAT of hepatitis B and C allowed to reach the biochemical answer (ALT and AST level normalization) in earlier terms, and to better control of cholestasis. In UDCA group were less frequency of hematologic side effects of peginterferon and peginterferon+ribavirin.
authors.forename: G M
authors.initials: GM
authors.lastname: Kurmanova
authors.forename: K B
authors.initials: KB
authors.lastname: Kurmanova
authors.forename: Sh S
authors.initials: ShS
authors.lastname: Sadykova
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D005260:Female; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage*; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D014580:Ursodeoxycholic Acid; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; C100416:peginterferon alfa-2a; D001663:Bilirubin